medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2012, Number 3

<< Back Next >>

Ann Hepatol 2012; 11 (3)

Serum adipocyte fatty acid binding protein in liver transplant recipients and the metabolic syndrome

Schmilovitz-Weiss H, Laish I, Levi Z, Monsselise Y, Harif Y, Braun M, Boaz M, Ben-Ari Z

Language: English
References: 36
Page: 343-349
PDF size: 93.61 Kb.


ABSTRACT

Background. Liver transplantation is often associated with metabolic derangements. Adipocyte fatty-acidbinding protein 4 (AFABP4) integrates inflammatory and metabolic responses. It has also been associated with metabolic syndrome in animal models and clinical studies in the general population. Aim. To determine the role of AFABP4 in post-transplant metabolic syndrome. Material and methods. Consecutive patients followed for at least 6 months after liver transplantation were tested for insulin resistance by homeostasis model assessment (HOMA). Serum levels of AFABP4 were tested by an enzyme-linked immunosorbent assay. Results. The study group included 76 patients (64.5% male, mean age 56.3 ± 12.4 years). Hypertension was present in 56.5%, hyperlipidemia in 69.7%, diabetes mellitus in 23.6%. Half of the patients met at least 3 criteria for metabolic syndrome. Serum AFABP4 levels (p ‹ 0.0001), HOMA index ≥ 2.5 vs. ‹ 2.5 (p ‹ 0.0002) and BMI ≥ 30 vs. ‹ 30 (p ‹ 0.0006) were significantly higher in patients with metabolic syndrome. Within the metabolic syndrome subgroup, AFABP4 levels significantly correlated with age, aspartate aminotransaminase level, waist circumference, and HOMA index. High AFABP4 significantly increased the odds of acquiring metabolic syndrome (OR 1.04, 95% CI 1.007-1.074, p = 0.017). On multiple logistic regression analysis, independent predictors of high AFABP4 were cryptogenic liver disease, steroid administration, high HOMA index, and a high degree of fatty infiltration. Conclusion. Prevalence of metabolic syndrome is significantly higher in liver transplant recipients than in the general population. AFABP4 may serve as a circulating biomarker in the clinical prediction/diagnosis of metabolic syndrome in patients post-liver transplantation.


REFERENCES

  1. Canzanello VJ, Schwartz L, Taler SJ, Textor SC, Wiesner RH, Porayko MK. Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporine A and tacrolimus (FK506). Liver Transpl Surg 1997; 3: 1-9.

  2. Stegall MD, Everson G, Schroter G, Bilir B, Karrer F, Kam I. Metabolic complications after liver transplantation. Diabetes, hypercholesterolemia, hypertension, and obesity. Transplantation 1995; 60: 1057-60.

  3. Saab S, Shpaner A, Zhao Y, Brito I, Durazo F, Han S, Farmer DG, et al. Prevalence and risk factors for diabetes mellitus in moderate term survivors of liver transplantation. Am J Transpl 2006; 6: 1890-5.

  4. Laryea M, Watt KD, Molinari M, Waish MJ, McAllister VC, Marotta PJ, Nashon B, et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transplant 2007; 13: 1109-14.

  5. Gisbert C, Prieto M, Berenguer M, Breto M, Carrasco D, de Huan. Hyperlipidemia in liver transplant recipients: prevalence and risk factors. Liver Transpl Surg 1997; 3: 416-22.

  6. Richards J, Gunson B, Johnson J, Neuberger J. Weight gain and obesity after liver transplantation. Transpl Int 2005; 18: 461-6.

  7. Correia MI, Rego LO, Lima AS. Post-liver transplant obesity and diabetes. Curr Opin Clin Nutr Metab Care 2003; 6: 457-60.

  8. Marchetti P, Navalesi R. The metabolic effects of cyclosporine and tacrolimus. J Endocrinol Invest 2000; 23: 482-90.

  9. Bigam DL, Pennington JJ, Carpentier A, Wanless IR, Hemming AW, Croxford R, Greig PD, et al. Hepatitis C-related cirrhosis: a predictor of diabetes after liver transplantation. Hepatology 2000; 32: 87-90.

  10. Delgado-Borrego A, Liu YS, Jordan AS, Agrawal S, Zhang H, Christafi M, Casson D, et al. Prospective study on liver transplant recipients with HCV infection: evidence of a causal relationship between HCV and insulin resistance. Liver Transpl 2008; 14: 193-201.

  11. Contos MJ, Cales W, Sterling RK, Luketic VA, Shiffman ML, Mills AS, Fisher RA, et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 2001; 7: 363-73.

  12. Cauble MS, Gilroy R, Sorrell MF, Mailliard ME, Sudan DL, Anderson JC, Wisecarver JL, et al. Lipoatrophic diabetes and end-stage liver disease secondary to nonalcoholic steato-hepatitis with recurrence after liver transplantation. Transplantation 2001; 71: 892-5.

  13. Angelico F, Del Ben M, Francioso S, Hurtova M, Battista S, Palmieri GP, Tisone G, et al. Recurrence of insulin resistant metabolic syndrome following liver transplantation. Eur J Gastroenterol Hepatol 2003; 15: 99-102.

  14. Malik S, Wong ND, Franklin SS, Kamath TV, L’Italien GJ, Pio JR, William GR. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110: 1245-50.

  15. Laish I, Braun M, Mor E, Sulkes J, Harif Y, Ben Ari Z. Metabolic syndrome in liver transplant recipients: prevalence, risk factors and association with cardiovascular events. Liver Transpl 2011; 17: 15-22.

  16. Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J, Wat NM, et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 2006; 52: 405-13.

  17. Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 2008; 7: 489-503.

  18. Maeda K, Cao H, Kono K, Gorgun CZ, Furuhashi M, Uysal KT, Cao Q, et al. Adipocyte/ macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab 2005; 1: 107-19.

  19. Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE, Spiegelman BM. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 1996; 274: 1377-9.

  20. Uysal KT, Scheja L, Wiesbrock SM, Bonner-Weir S, Hotamisligil GS. Improved glucose and lipid metabolism in genetically obese mice lacking aP2. Endocrinology 2000; 141: 3388-96.

  21. Milner KL, van der Poorten D, Xu A, Bugianesi E, Kench JG, Lam KS, Chisholm DJ, et al. Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology 2009; 49: 926-34.

  22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.

  23. McAuley KA, Williams SM, Mann JI, Waiker RJ, Lewis-Barned NJ, Temple LA, Duncan AW. Diagnosing insulin resistance in the general population. Diabetes Care 2001; 24: 460-64.

  24. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.

  25. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/ National Heart, Lung and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-52.

  26. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-9.

  27. Mells G, Neuberger J. Reducing the risks of cardiovascular disease in liver allograft recipients. Transplantation 2007; 83: 1141-50.

  28. Boord JB, Maeda K, Makowski L, Babaev VR, Fazio S, Linton MF, Hotamisligil G. Combined adipocyte-macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice. Circulation 2004; 110: 1492-8. 29.

  29. Reinehr T, Stoffel-Wagner B, Roth CL. Adipocyte fatty acid-binding protein in obese children before and after weight loss. Metabolism 2007; 56: 1735-41.

  30. Makowski L, Boord JB, Maeda K, Babaev VR, Uysal KT, Morgan MA, Parker RA, et al. Lack of macrophage fatty-acidbinding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med 2001; 7: 699-705.

  31. Makowski L, Hotamisligil GS. Fatty acid binding proteins - the evolutionary crossroads of inflammatory and metabolic responses. J Nutr 2004; 134: 2464S-8S.

  32. Angelico F, Del Ben M, Conti R, Francioso S, Feole K, Fiorello S, Cavallo MG, et al. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2005; 90: 1578-82.

  33. Ong J, Younossi ZM, Reddy V, Price LL, Gramlich T, Mayes J, Boparai N. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transplant 2001; 7: 797-801.

  34. Malik SM, de-Vera ME, Fontes P, Shaikh O, Ahmad J. Outcome after liver transplantation for NASH cirrhosis. Am J Transpl 2009; 9: 782-93.

  35. Angelico F, Del Ben M, Francioso S, Hurtova M, Battista S, Palmieri GP, Tisone G, et al. Recurrence of insulin resistant metabolic syndrome following liver transplantation. Eur J Gastroenterol Hepatol 2003; 15: 99-102.

  36. Pagadala M, Dasarathy S, Eghtesad B, McCullough AJ. Posttransplant metabolic syndrome: an epidemic waiting to happen. Liver Transpl 2009; 15: 1662-70.




2020     |     www.medigraphic.com